J. KNIPPER & COMPANY — Docetaxel Importer Profile
Pharmaceutical Importer · #5 buyer for Docetaxel · $600.0K import value · 12 shipments · UNITED STATES · DGFT Verified
J. KNIPPER & COMPANY is the #5 importer of Docetaxel from India with $600.0K in import value and 12 verified shipments. J. KNIPPER & COMPANY holds a 1.5% market share in Docetaxel imports based in UNITED STATES. The company sources from 1 verified supplier across 10 formulations shipped to 1 country. Overall, J. KNIPPER & COMPANY imports 28 pharmaceutical products worth $68.5M across 14 therapeutic categories.
J. KNIPPER & COMPANY — Docetaxel Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Docetaxel to J. KNIPPER & COMPANY?
Verified from 12 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| ALEMBIC PHARMACEUTICALS LIMITED | $600.0K | 12 | 100.0% |
J. KNIPPER & COMPANY sources Docetaxel from 1 verified Indian supplier based on 12 customs records. The primary supplier is ALEMBIC PHARMACEUTICALS LIMITED accounting for 100.0% of imports.
How Does J. KNIPPER & COMPANY Compare to Nearest Docetaxel Importers?
Buyers ranked immediately above and below #5 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | FRESENIUS KABI COLOMBIA SAS | COLOMBIA | $1.1M | 28 | $39.1K |
| 10 | CPC "BIOCON" LLC | UKRAINE | $707.3K | 18 | $39.3K |
| 5 | J. KNIPPER & COMPANY ★ | UNITED STATES | $600.0K | 12 | $50.0K |
| 12 | VE PHARMA INC | PHILIPPINES | $598.9K | 57 | $10.5K |
| 14 | VE PHARMA INC. | PHILIPPINES | $543.2K | 24 | $22.6K |
J. KNIPPER & COMPANY ranks #5 among 641 Docetaxel importers from India. Average shipment value of $50.0K compared to the market average of $19.4K. The closest competitors by value are FRESENIUS KABI COLOMBIA SAS and CPC "BIOCON" LLC.
Where Does J. KNIPPER & COMPANY Import Docetaxel To?
Destination countries from 12 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $600.0K | 12 | 100.0% |
J. KNIPPER & COMPANY imports Docetaxel to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $600.0K.
What Docetaxel Formulations Does J. KNIPPER & COMPANY Import?
| Formulation | Value | Shipments |
|---|---|---|
| DOCETAXEL INJ USP 80MG/8ML AP US | $100.0K | 2 |
| DOCETAXEL INJ USP 160MG/16 ML AP US | $100.0K | 2 |
| DOCETAXEL INJ USP 160MG/16ML AP US | $50.0K | 1 |
| DOCETAXEL INJ USP 20MG/2ML AP US | $50.0K | 1 |
| DOCETAXEL INJ USP 160MG/ 16ML AP US (252 | $50.0K | 1 |
| DOCETAXEL INJ USP 160MG/16ML_AP_US(2544NOS)NOS | $50.0K | 1 |
| DOCETAXEL INJ USP 80MG/8ML_AP_US(4992 NOS)NOS | $50.0K | 1 |
| DOCETAXEL INJ USP 20MG/2ML_AP_US(9612 NOS)NOS | $50.0K | 1 |
| DOCETAXEL INJ USP 160MG/16ML AP US (5184NOS) | $50.0K | 1 |
| DOCETAXEL INJ USP 160MG/ 16ML AP US | $50.0K | 1 |
J. KNIPPER & COMPANY imports 10 distinct Docetaxel formulations from India. The top formulation is DOCETAXEL INJ USP 80MG/8ML AP US with 2 shipments worth $100.0K.
Regulatory Requirements: Importing Docetaxel into United States
What J. KNIPPER & COMPANY and other importers must comply with to import Docetaxel from India
Regulatory Authority
U.S. Food and Drug Administration (FDA)
Approval Process for Generic Docetaxel
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
GMP Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Import Licence & Documentation
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
Labeling & Packaging
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Docetaxel from India and How Much Does J. KNIPPER & COMPANY Import?
India exported $12.4M worth of Docetaxel through 2,634 shipments from 253 suppliers to 120 countries, serving 641 buyers globally. J. KNIPPER & COMPANY imports $600.0K of this total, accounting for 1.5% of India's Docetaxel exports with 12 shipments from UNITED STATES. This is verified from 12 customs shipment records covering 10 distinct formulations.
What Is the Average Order Value for J. KNIPPER & COMPANY's Docetaxel Imports?
J. KNIPPER & COMPANY's average Docetaxel order value is $50.0K per consignment, based on 12 shipments totaling $600.0K. J. KNIPPER & COMPANY is based in UNITED STATES and ranks #5 among all Docetaxel importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Docetaxel to J. KNIPPER & COMPANY?
J. KNIPPER & COMPANY sources Docetaxel from 1 verified Indian supplier: ALEMBIC PHARMACEUTICALS LIMITED ($600.0K, 100.0%). This is based on 12 customs records.
How Does J. KNIPPER & COMPANY Compare to Other Docetaxel Importers?
J. KNIPPER & COMPANY ranks #5 among 641 Docetaxel importers from India with a 1.5% market share. The top 3 importers are MYLAN INSTITUTIONAL INC 2898 ($3.3M), FRESENIUS KABI DEUTSCHLAND GMBH ($2.5M), FRESENIUS KABI COLOMBIA SAS ($1.1M). J. KNIPPER & COMPANY processed 12 shipments from UNITED STATES.
What Other Oncology Products Does J. KNIPPER & COMPANY Import?
J. KNIPPER & COMPANY also imports these oncology products. Each links to the detailed product page.
About J. KNIPPER & COMPANY
J. KNIPPER & COMPANY imports 28 products worth $68.5M. Beyond Docetaxel, top products include Celecoxib, Losartan, Valsartan, Doxycycline, Azithromycin. View the complete J. KNIPPER & COMPANY profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Docetaxel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Docetaxel shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: J. KNIPPER & COMPANY matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as J. KNIPPER & COMPANY's capped import value divided by total capped export value for Docetaxel across all Indian exporters.
- 5.Verified Records: This page is backed by 12 individual customs records matching J. KNIPPER & COMPANY importing Docetaxel, covering 10 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 120+ countries, 641+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Docetaxel Import Data for J. KNIPPER & COMPANY
Access order-level details, pricing data, supplier connections, and competitive analysis for J. KNIPPER & COMPANY's Docetaxel imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
J. KNIPPER & COMPANY
Full Company Profile →
28 products · $68.5M total trade · 14 categories
J. KNIPPER & COMPANY × Docetaxel
Verified from customs records
Company Overview
Top Products by J. KNIPPER & COMPANY
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for J. KNIPPER & COMPANY.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Docetaxel. For current order-level data, contact TransData Nexus.